Latest Breaking News On - லாரிமார் சிகிச்சை - Page 2 : comparemela.com

Share this article Share this article NEW YORK, June 1, 2021 /PRNewswire/  Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ( Larimar or the Company ) (NASDAQ: LRMR).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Larimar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  On May 25, 2021, Larimar issued a press release announc[ing] that the United States Food and Drug Administration (FDA) has placed a clinical hold on the CTI-1601 clinical program and that the company will not be closing a previously announced private placement financing. CTI-1601 is a recombinant fusion protein intended to deliver human frataxin into the mitochondria of patients with FA who are unable to produce enough of this essential protein.   The press release further stated that [t]he clinic

New yorkUnited statesFrance generalLos angelesAbrahaml pomerantzRoberts willoughbyLarimar therapeutics incDrug administrationPomerantz firmLarimar therapeuticsUnited states foodPomerantz llpபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்பிரான்ஸ் ஜநரல்லாஸ் ஏஞ்சல்ஸ்